Recent Posts
- Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
- Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis
- Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
- Attralus Receives European Medicines Agency Committee for Orphan Medicinal Products (COMP) Positive Opinions for AT-02 for the Treatment of Both ATTR and AL Amyloidosis
- Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
Recent Comments
No comments to show.